These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39171842)

  • 1. Effect of Genetic Polymorphisms of ABCB1, ABCG2, and SLC22A1 on the Steady-State Plasma Concentrations of Lamotrigine in Treatment-Resistant Depressed Patients Treated With Lamotrigine Augmentation Therapy.
    Tomori Y; Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Clin Neuropharmacol; 2024 Sep-Oct 01; 47(5):163-167. PubMed ID: 39171842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2019 Feb; 41(1):86-90. PubMed ID: 30489548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
    Klarica Domjanović I; Lovrić M; Trkulja V; Petelin-Gadže Ž; Ganoci L; Čajić I; Božina N
    Br J Clin Pharmacol; 2018 Sep; 84(9):2106-2119. PubMed ID: 29791014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy.
    Šušak Sporiš I; Božina N; Klarica Domjanović I; Sporiš D; Bašić S; Bašić I; Lovrić M; Ganoci L; Trkulja V
    Fundam Clin Pharmacol; 2024 Apr; 38(2):351-368. PubMed ID: 37793994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
    Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients.
    Zhou Y; Wang X; Li H; Zhang J; Chen Z; Xie W; Zhang J; Li J; Zhou L; Huang M
    Drug Metab Pharmacokinet; 2015 Aug; 30(4):282-7. PubMed ID: 26213157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the
    Tan Y; Cao K; Ren G; Qin Z; Zhao D; Li N; Chen X; Xia Y; Lu Y
    Xenobiotica; 2020 Feb; 50(2):237-243. PubMed ID: 31021303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2020 Aug; 42(4):631-635. PubMed ID: 31985552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of
    Maeda A; Ando H; Irie K; Hashimoto N; Morishige JI; Fukushima S; Ebi H; Uchida K; Iwata H; Sawaki M
    Anticancer Res; 2023 Mar; 43(3):1283-1289. PubMed ID: 36854511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy.
    Shen CH; Zhang YX; Lu RY; Jin B; Wang S; Liu ZR; Tang YL; Ding MP
    Epilepsy Res; 2016 Nov; 127():186-190. PubMed ID: 27610747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
    Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.
    Ghafouri H; Ghaderi B; Amini S; Nikkhoo B; Abdi M; Hoseini A
    Tumour Biol; 2016 Jun; 37(6):7901-6. PubMed ID: 26700668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
    Lal S; Wong ZW; Sandanaraj E; Xiang X; Ang PC; Lee EJ; Chowbay B
    Cancer Sci; 2008 Apr; 99(4):816-23. PubMed ID: 18377430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
    Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
    Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.